BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29789640)

  • 21. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation.
    Garcez ML; Jacobs KR; Guillemin GJ
    Neurotox Res; 2019 Aug; 36(2):424-436. PubMed ID: 31089885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
    Rowe CC; Bourgeat P; Ellis KA; Brown B; Lim YY; Mulligan R; Jones G; Maruff P; Woodward M; Price R; Robins P; Tochon-Danguy H; O'Keefe G; Pike KE; Yates P; Szoeke C; Salvado O; Macaulay SL; O'Meara T; Head R; Cobiac L; Savage G; Martins R; Masters CL; Ames D; Villemagne VL
    Ann Neurol; 2013 Dec; 74(6):905-13. PubMed ID: 24448836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
    Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
    Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
    Martins LB; Silveira ALM; Teixeira AL
    Curr Neuropharmacol; 2023; 21(2):260-272. PubMed ID: 36154606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.
    Kuwano N; Kato TA; Setoyama D; Sato-Kasai M; Shimokawa N; Hayakawa K; Ohgidani M; Sagata N; Kubo H; Kishimoto J; Kang D; Kanba S
    J Affect Disord; 2018 Apr; 231():74-82. PubMed ID: 29454180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients.
    Laiterä T; Paananen J; Helisalmi S; Sarajärvi T; Huovinen J; Laitinen M; Rauramaa T; Alafuzoff I; Remes AM; Soininen H; Haapasalo A; Jääskeläinen JE; Leinonen V; Hiltunen M
    J Alzheimers Dis; 2017; 55(3):995-1003. PubMed ID: 27802227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.